X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.486
-0.003 (-0.69%)
Jan 22, 2025, 2:09 PM EST - Market open
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 93 employees as of December 31, 2023. The number of employees increased by 23 or 32.86% compared to the previous year.
Employees
93
Change (1Y)
23
Growth (1Y)
32.86%
Revenue / Employee
$12,075
Profits / Employee
-$180,204
Market Cap
82.87M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 93 | 23 | 32.86% |
Dec 31, 2022 | 70 | -13 | -15.66% |
Dec 31, 2021 | 83 | 11 | 15.28% |
Dec 31, 2020 | 72 | 14 | 24.14% |
Dec 31, 2019 | 58 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
XFOR News
- 9 days ago - X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand - GlobeNewsWire
- 7 weeks ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) - GlobeNewsWire
- 3 months ago - X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024 - GlobeNewsWire
- 4 months ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire